Floatz logo

Zilovertamab

Immune System Diseases

Oncternal Therapeutics, Incmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Immune System Diseases cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 2BB
LIDOCAINE
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Fludarabine
Indapta Therapeutics, INC.
Phase 2BB
Strimvelis
Fondazione Telethon
Phase 4B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B

View all 38 →

Same molecule, other indications

Zilovertamab is also rated in:

mantle cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
60 / 100
View asset →
lymphatic system disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →